Olaparib Oral Product + Olaparib Oral Product in combination with Durvalumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Breast Cancer
Conditions
Triple Negative Breast Cancer
Trial Timeline
Oct 4, 2018 → Jun 30, 2022
NCT ID
NCT03167619About Olaparib Oral Product + Olaparib Oral Product in combination with Durvalumab
Olaparib Oral Product + Olaparib Oral Product in combination with Durvalumab is a phase 2 stage product being developed by AstraZeneca for Triple Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03167619. Target conditions include Triple Negative Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03167619 | Phase 2 | Completed |
Competing Products
20 competing products in Triple Negative Breast Cancer